(redirected from Concurrent Chemoradiotherapy)
CCRTConcurrent Chemoradiotherapy (oncology)
CCRTCritical Care Response Team (various locations)
CCRTCore Conflictual Relationship Theme
CCRTComputer-Controlled Radiation Therapy
CCRTCape Cod Rail Trail (Massachusetts, USA)
CCRTConseil Canadien de la Réadaptation et du Travail (Canadian Council on Rehabilitation and Work)
CCRTCertified Canine Rehabilitation Therapist (veterinary care)
CCRTCommunity Crisis Response Team
CCRTContract, Cost-Reimbursement Type
CCRTContingency Command Review Team
CCRTContractor Concept Review Team
CCRTCredentialed Clinical Research Trainer
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Sun, "Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial," The Lancet Oncology, vol.
As a chemo- and radiosensitive tumor, the current standard treatment for locally advanced NPC is concurrent chemoradiotherapy [4,5], which can result in 5-year survival and disease-free rates up to 70% [6,7].
Concurrent chemoradiotherapy (CCRT) improves overall survival (OS), disease-free survival (DFS) and local regional control and has become the standard treatment for squamous cell carcinoma in head and neck (SCCHN).
Besides the expected synergistic effects of the two different treatment modalities (TMZ and radiotherapy), a possible disadvantage of concurrent chemoradiotherapy is that it bears the risk of increased toxicity and side effects.
Concurrent chemoradiotherapy was performed with radiotherapy 70.2 Gy and chemotherapy of CDDP and VP16 for 4 times under the consideration of unresectable neck metastases.
However, there are the risks of recurrence because of remaining micrometastases after RHy, and adjuvant radiotherapy or concurrent chemoradiotherapy (CCRT) are needed to improve survival.
Therefore, recent studies have focused on the use of concurrent chemoradiotherapy (CCRT) to achieve results with respect to disease control and survival, as well as to preserve organ function so that patients can speak and eat as normally as possible.
Recently, a new study has reported that neoadjuvant chemotherapy followed by radical hysterectomy (NAC+RH) improves survival of patients with locally advanced cervical cancer in comparison to concurrent chemoradiotherapy (CCRT) (11).
Most cases were treated by concurrent chemoradiotherapy (66%) followed by adjuvant chemotherapy.
The standard therapy is IAIC followed by surgical intervention and postoperative concurrent chemoradiotherapy. Therefore, this retrospective study investigated how the IAIC-surgery interval affects outcomes of treatment for locally advanced OSCC.
Full browser ?